Table 2.
Plasma levels of tested parameters and CA 125 and SCC-Ag in patients with cervical cancer and in control group
| Groups tested | M-CSF (pg/mL) | MMP-2 (ng/mL) | TIMP-2 (ng/mL) | SCC-Ag (U/mL) | CA 125 (U/mL) |
|---|---|---|---|---|---|
| Cervical cancer (median, range) | |||||
| Stage I | 422.55a (102.15–2513.75) | 200.00 (124.84–352.00) | 70.00a (40.00–160.00) | 1.29 (0.38–2.20) | 14.40 (6.60–49.60) |
| Stage II | 510.55a (95.26–1304.80) | 218.00 (129.80–379.00) | 71.50 (26.93–120.00) | 1.20 (0.45–5.90) | 17.40a (4.40–77.41) |
| Stages III and IV | 578.50a (113.05–2511.95) | 221.00a (140.50–351.96) | 84.60b/c (50.00–156.00) | 1.20 (0.30–14.10) | 25.65 a/b (6.34–120.10) |
| Total group | 510.55a (95.23–2513.75) | 214.00 (124.84–379.00) | 76.00a (26.93–160.00) | 1.20 a (0.30–14.10) | 17.99 a (4.40–120.10) |
| Control groups (median, range) | |||||
| Healthy women | 251.50 (119.63–935.29) | 202.95 (24.30–397.20) | 87.25 (42.50–132.50) | 0.75 (0.40–1.60) | 11.70 (3.50–36.60) |
a Statistically significant when patients with CC compared with healthy women.
b Statistically significant when patients with CC stages III and IV compared with patients with CC stage I
c Statistically significant when patients with CC stages III and IV compared with patients with CC stage II